Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.

ABSTRACT:

Introduction

Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options. Angiogenesis plays a fundamental role in the development of drug-resistance in ovarian cancer. Anlotinib, a novel oral multi-targeted tyrosine kinase inhibitor which targets a board spectrum of angiogenesis-associated growth factor receptors, has shown promising anti-tumor efficacy in clinical trials. Herein, we report a case of ovarian cancer treated with anlotinib plus etoposide after secondary cytoreductive surgery.

Patient concerns

A 45-year-old female with primary platinum-resistant ovarian cancer who progressed rapidly after the first cytoreductive surgery, the second cytoreductive surgery, and several lines of treatment. The patient refused to receive i

SUBMITTER: Sun L 

PROVIDER: S-EPMC7253621 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature